FDA Clears Update of AI-Enabled Imaging Contour Models
Updates to Contour ProtegeAI 4.0 reportedly include enhanced algorithms for radiation oncology segmentation and molecular radiotherapy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the updated version of Contour ProtegeAI® 4.0 (MIM Software), a platform that provides automated deep learning segmentation for organs at risk (OARs).
Contour ProtegeAI 4.0 offers improved algorithms for radiation oncology as well as improvements for molecular radiotherapy, according to MIM Software.
“Over the past several months, the MIM Software team has worked hard to focus this new version on improving our contouring performance,” noted Jay Obman, a product manager at MIM Software, Inc. “The initial testing has shown a good improvement in our overall contour quality, and I’m excited for our users to reap the benefits of those improvements as well as some new contours we’ve added.”
The company adds that the software facilitates standardized, efficient workflows and provides automated preparation for physician target volume (PTV) contouring. Contour ProtegeAI 4.0 also integrates with Eclipse™, RayStation®, Monaco® and Pinnacle, according to MIM Software.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
